CIK 0002022626 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Upstream Bio, Inc.
Sign in to watch- Ticker
- UPB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-208-2466
- Business address
- 890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $27,604
- in 5 filings
Net −$27,604. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-06 | Deykin Aaron Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +165,000 | 165,000 | ||
| 2025-02-06 | Ambrose Allison General Counsel | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2024-12-16 | Ambrose Allison General Counsel | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-10-15 | AI Upstream LLC 10% owner | Purchase 10b5-1 | +1,175,000 | $17.00 | $20.0M | 1,175,000 |
| 2024-10-15 | AI Upstream LLC 10% owner | Conversion 10b5-1 | +3,147,000 | 4,322,000 | ||
| 2024-10-15 | AI Upstream LLC 10% owner | Conversion 10b5-1 | +1,172,410 | 5,494,410 | ||
| 2024-10-15 | AI Upstream LLC 10% owner | Conversion · Series A Convertible Preferred Stock 10b5-1 | −3,147,000 | 0 | ||
| 2024-10-15 | AI Upstream LLC 10% owner | Conversion · Series B Convertible Preferred Stock 10b5-1 | −1,172,410 | 0 | ||
| 2024-10-15 | Chimovits Erez Director | Conversion | +721,956 | 973,716 | ||
| 2024-10-15 | Chimovits Erez Director | Purchase | +165,000 | $17.00 | $2.8M | 1,138,716 |
| 2024-10-15 | Chimovits Erez Director | Conversion | +2,887,833 | 3,894,873 | ||
| 2024-10-15 | Chimovits Erez Director | Purchase | +660,000 | $17.00 | $11.2M | 4,554,873 |
| 2024-10-15 | Chimovits Erez Director | Conversion · Series A redeemable convertible preferred stock | −524,500 | 0 | ||
| 2024-10-15 | Chimovits Erez Director | Conversion · Series A redeemable convertible preferred stock | −2,098,000 | 0 | ||
| 2024-10-15 | Chimovits Erez Director | Conversion · Series B redeemable convertible preferred stock | −197,456 | 0 | ||
| 2024-10-15 | Chimovits Erez Director | Conversion · Series B redeemable convertible preferred stock | −789,833 | 0 | ||
| 2024-10-15 | ORBIMED ADVISORS LLC Director | Conversion | +721,956 | 973,716 | ||
| 2024-10-15 | ORBIMED ADVISORS LLC Director | Purchase | +165,000 | $17.00 | $2.8M | 1,138,716 |
| 2024-10-15 | ORBIMED ADVISORS LLC Director | Conversion | +2,887,833 | 3,894,873 | ||
| 2024-10-15 | ORBIMED ADVISORS LLC Director | Purchase | +660,000 | $17.00 | $11.2M | 4,554,873 |
Page 3 of 4 · 72 trades